Nymox Provides Update on Current Corporate Activities and Milestones

Nymox Pharmaceutical Corporation (NYMX) is pleased to provide a current January 2020 update on several important corporate activities and achievements since the last update in October 2019.

The Company recently received the necessary information regarding the formatting and content of its upcoming regulatory filings for its Fexapotide Triflutate (FT) first in class injectable drug to treat the symptoms of prostate enlargement (BPH) in men. The Company is proceeding to integrate safety data from its four Phase I and Phase II BPH clinical trials as well as the safety data from Prostate Cancer Study NX03-0040 into the final dataset (that also includes 4 Phase 3 trials) that will be part of the New Drug Application (NDA) submission. The filings seeking approvals in the US and in Europe are now targeted for the first half of 2020 in both jurisdictions. At this point, the Company does not have any barriers to report and does not expect any delays.

Nymox is further pleased to report that another peer review publication (as anticipated in the Company’s October 21, 2019 Press Release) was recently accepted and published in Research and Reports in Urology. This publication discusses the selective cellular ablation capabilities of Fexapotide Triflutate to induce apoptosis (natural cell death) in prostate glandular cells which are a major part of the prostate enlargement which defines benign prostatic hyperplasia. Selective pharmaco-ablation is achieved while leaving the nerve cells and urethra and other nearby tissues (all crucial for normal sexual function) unaffected. In fact, the Company has previously reported a statistically significant improvement in sexual function reported by men treated with FT for BPH in its U.S. Phase III long-term follow up studies.

A fourth new and important peer review article is expected to appear in the near term. Further information will be provided when the new article appears.

Dr Paul Averback, CEO commented, “We are very pleased to provide these positive substantiated updates to shareholders today. Now, after many months of intensive work with our regulatory advisors and experts, we are confident that we have the needed clarity concerning the optimal formatting and content protocols being undertaken. The Company is currently highly focused on expeditiously completing the final legs of its regulatory pre-filing responsibilities.”

The new peer review article reported in January 2020 and published in Research and Reports in Urology provided detailed documentation of the selective pharmco-ablation mechanism of action of FT, demonstrating the highly selective reduction of prostate cells which comprises one of the most important underlying reasons for the highly superior safety and efficacy of Fexapotide.

https://finance.yahoo.com/news/nymox-provides-current-corporate-activities-143010396.html